3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
784
Lung Neoplasms
346
Small Cell Lung Carcinoma
146
Adenocarcinoma of Lung
71
Neoplasms
44
Neoplasm Metastasis
34
Adenocarcinoma, Bronchiolo-Alveolar
30
Colorectal Neoplasms
25
Ovarian Neoplasms
24
Carcinoma
24
Lung Diseases
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Breast Neoplasms
17
Mesothelioma
16
Thoracic Neoplasms
15
Respiratory Tract Neoplasms
15
Mesothelioma, Malignant
15
Pancreatic Neoplasms
13
NSCLC
13
Endometrial Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Carcinoma, Bronchogenic
12
Adenocarcinoma
12
Melanoma
11
Triple Negative Breast Neoplasms
10
Stomach Neoplasms
10
Brain Neoplasms
10
Respiratory Tract Diseases
9
Head and Neck Neoplasms
9
Carcinoma, Squamous Cell
9
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Carboplatin
×
Thoracic
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA